ISPOR MEDICATION ADHERENCE AND PERSISTENCE SPECIAL INTEREST GROUP (MAP) - Medication Adherence of Specific Diseases Working Group

Chair:
Femida Gwadry-Sridhar, PhD, RPh, MSc, Assistant Professor, Departments of Medicine, Physiology and Pharmacology, and Computer Science, University of Western Ontario; Associate Director, Critical Care Research Network; Director of Health Informatics, Lawson Health Research Institute; CIHR New Investigator-Knowledge Translation, London, Ontario, Canada

Medication Adherence of Specific Diseases Working Group

Access for Leadership Group Members Only

How to login

User name: first part of the email address (before @)
e.g. for jdoe@ispor.org it should be jdoe)
Password: ISPOR Member ID.

Click here for login help

Leadership Group:
Dyfrig Hughes, PhD, MSc, Professor of Pharmacoeconomics, Bangor University Centre for Health Economics and Medicines Evaluation, IMSCaR, Bangor University, Wales, UK
Mickaël Hiligsmann, PhD, Postdoctoral Researcher, Department of Internal Medicine & Department of Clinical Epidemiology and Medical Technology Assessment & CAPHRI Research Institute, Maastricht University, Maastricht, the Netherlands
Lincy Lal, Pharm.D, PhD, Senior Research Consultant – Healthcare, Ingenix Consulting, Missouri City, TX, USA
Elizabeth Manias RN, BPharm, MPharm, MNStud, PhD, FRCNA, MPS, Professor, Associate Head of Research, School of Nursing and Social Work, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Carlton, Victoria, Australia
Maribel Salas MD, DSc, MSc, FACP, Medical Director, US Patient Safety, AstraZeneca, Wilmington, DE and CCEB, University of Pennsylvania, Philadelphia PA, USA

Goal:
To conduct systematic reviews of medication adherence for specific diseases, to critically appraise methods to improve adherence and to recommend good clinical or patient self-management (if possible), and/or to assess the cost of medication nonadherence.

Work Product 1:
Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review and meta-analysis by the ISPOR Medication Adherence & Persistence Special Interest Group
Accepted for publication in Value in Health: 3/16/13
Authors

Femida Gwadry-Sridhar, BSc Phm, MSc, PhD Femida Gwadry-Sridhar, PhD, RPh, MSc, Assistant Professor, Departments of Medicine, Physiology and Pharmacology, and Computer Science, University of Western Ontario; Associate Director, Critical Care Research Network; Director of Health Informatics, Lawson Health Research Institute; CIHR New Investigator-Knowledge Translation
Elizabeth Manias RN, BPharm, MPharm, MNStud, PhD, FRCNA, MPS, Professor, Associate Head of Research, School of Nursing and Social Work, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Carlton, Victoria, Australia
Lincy Lal, Pharm.D, PhD, Senior Research Consultant – Healthcare, Ingenix Consulting, Missouri City, TX, USA
Maribel Salas MD, DSc, MSc, FACP, Medical Director, US Patient Safety, AstraZeneca, Wilmington, DE and CCEB, University of Pennsylvania, Philadelphia PA, USA
Maja Grubisic, Collaboration for Outcomes Research and Evaluation (CORE), Department of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
Dyfrig Hughes, PhD, MSc, Professor of Pharmacoeconomics, Bangor University Centre for Health Economics and Medicines Evaluation, IMSCaR, Bangor University, Wales, UK

Elizabeth Manias RN, BPharm, MPharm, MNStud, PhD, FRCNA, MPS, Professor, Associate Head of Research, School of Nursing and Social Work, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Carlton, Victoria, Australia
Femida Gwadry-Sridhar, BSc Phm, MSc, PhD Femida Gwadry-Sridhar, PhD, RPh, MSc, Assistant Professor, Departments of Medicine, Physiology and Pharmacology, and Computer Science, University of Western Ontario; Associate Director, Critical Care Research Network; Director of Health Informatics, Lawson Health Research Institute; CIHR New Investigator-Knowledge Translation
Peter Dale, MSc, BSc, Manager GHO, GlaxoSmithKline, Uxbridge, UK
Ian Barron, PhD, PharmD, Research Fellow, University of Dublin, Trinity College Department of Pharmacology & Therapeutics, Dublin, Ireland

Work Product 2:
Diabetes Patient Good Self-Management Practices: A Systemic Review, Critical Appraisal, and Recommendations by the ISPOR Medication Adherence & Persistence Special Interest Group
Lead Author: Femida Gwadry-Sridhar, PhD, RPh, MSc, Assistant Professor, Departments of Medicine, Physiology and Pharmacology, and Computer Science, University of Western Ontario; Associate Director, Critical Care Research Network; Director of Health Informatics, Lawson Health Research Institute; CIHR New Investigator-Knowledge Translation, London, Ontario, Canada
Authors

Maribel Salas MD, DSc, MSc, FACP, Medical Director, US Patient Safety, AstraZeneca, Wilmington, DE and CCEB, University of Pennsylvania, Philadelphia PA, USA
Elizabeth Manias RN, BPharm, MPharm, MNStud, PhD, FRCNA, MPS, Professor, Associate Head of Research, School of Nursing and Social Work, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Carlton, Victoria, Australia
Abhijit Gadkari, PhD, RPh, Manager, US Outcomes Research, Merck & Co., Inc., Philadelphia, PA, USA
Scott Leslie, MPH, Statistician, Prescription Solutions, Costa Mesa, CA, USA
Anuja Roy, PhD, MBA, Senior Manager, Global Health Economics & Outcomes Research, Takeda Pharmaceuticals International, Inc, Deerfield IL, USA
Lincy Lal, Pharm.D, PhD, Senior Research Consultant – Healthcare, Ingenix Consulting, Missouri City, TX, USA
Vernon Schabert, PhD, BA, Principal, Health Economics and Outcomes Research IMS Health, Santa Barbara, CA, USA
Stacey Guy, BSocSci, Hons Psych, Masters Psych, Research Assistant, I-THINK Research Lawson Health Research Institute, London, Ontario, Canada

Description: With the increased burden of health care resources, self‐management is being touted as an important strategy to improve medication. There are many definitions around self‐management strategies and interventions which have varied results. A review of strategies and their respective success or failures will be examined. Using a systematic review we will consider interventions that are used for self‐management. We will look at what types of interventions are used for the patient’s self-management of diabetes and will assess the efficacy or effectiveness of self‐management strategies on persistence and possibly clinical outcomes. We will suggest recommendations for patient good self-management practices.

Work Product 3:
Interventions to Improve Dyslipidemia Medication Adherence : A Systematic Review and Critical Analysis by the ISPOR Medication Adherence & Persistence Special Interest Group
Lead Author: Maribel Salas MD, DSc, MSc, FACP, Medical Director, US Patient Safety, AstraZeneca, Wilmington, DE and CCEB, University of Pennsylvania, Philadelphia PA, USA
Authors

Femida Gwadry-Sridhar, PhD, RPh, MSc, Assistant Professor, Departments of Medicine, Physiology and Pharmacology, and Computer Science, University of Western Ontario; Associate Director, Critical Care Research Network; Director of Health Informatics, Lawson Health Research Institute; CIHR New Investigator-Knowledge Translation
Elizabeth Manias RN, BPharm, MPharm, MNStud, PhD, FRCNA, MPS, Professor, Associate Head of Research, School of Nursing and Social Work, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Carlton, Victoria, Australia
Dyfrig Hughes, PhD, MSc, Professor of Pharmacoeconomics, Bangor University Centre for Health Economics and Medicines Evaluation, IMSCaR, Bangor University, Wales, UK

Description: Systematic literature review to examine medication adherence in patients with dyslipidemia. Interventions to improve patient adherence with dylipidemia treatment will be examined. Qualitative and quantitative analysis will be conducted to determine which interventions have a positive impact on improving compliance. TrialStat SRS will be utilized for the analysis. The review process will consist of three levels of inclusion/exclusion determination with two reviewers per study at each level. TrialStat SRS will be utilized for the analysis. Qualitative and quantitative analysis will be conducted to determine which interventions have a positive impact on improving adherence.

Timeline:

Activity	Date
Identify paper authors	Completed
Identify key terms for literature searching	Completed
Conduct the literature search	Completed
Develop and test data extraction tool	Completed
Finalize entry of papers into data extraction tool	Completed
Review papers for quality using Nichol et al tool and perform inter-rater reliability checking for quality tool	Completed
Undertake a quality appraisal of papers identified	Completed
Extract the treatment intervention and medication adherence information from the papers identified	Completed
Develop consensus on the effect of treatment intervention and medication adherence	Completed
Develop outline paper	Completed
Assign sections of the paper to authors	Completed
Develop draft paper	Completed
Draft paper reviewed by ISPOR Medication Adherence & Persistence SIG Review Group	February 2012
Revise draft paper based on comments	March 2012
Submit to Value in Health	April 2012

Activities:
PMS39: Most Effective Adherence-Enhancing Interventions For Osteoporosis Medications
( Poster Session II )
May 2011 – ISPOR 16th Annual International Meeting, Poster Presentation, Baltimore, MD, USA

Several members of the Medication Adherence and Persistence SIG Specific Diseases Working Group, in collaboration with the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), will be speakers at an ESCEO-ISPOR Symposium which will be held during the 12th European Congress of Osteoporosis and Osteoarthritis, March 21-24, 2012, in Bordeaux, France. The program for this symposium may be seen here. The ESCEO homepage is here www.esceo.org

If you are interested in joining this ISPOR Special Interest Group, please complete the Special Interest Group Application Form.

ISPOR MEDICATION ADHERENCE AND PERSISTENCE SIG (MAP) MAIN PAGE